Image Source: Express Pharma
Biocon Pharma Limited, a fully owned subsidiary of Biocon Ltd, has obtained tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP in several strengths. This regulatory achievement further enhances Biocon's increasing footprint in the US generics market and adds to its increasing portfolio of high-value, complex drug products.
Tentative US FDA Approval for Rivaroxaban:
Biocon Pharma has received tentative approval for its ANDA for Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. Rivaroxaban is an oral anticoagulant that is commonly prescribed to treat and prevent deep vein thrombosis (DVT), pulmonary embolism (PE), and to lower the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Part of Broader US FDA Approvals
The Rivaroxaban approval is followed by US FDA final approvals for two other lead drugs: Lenalidomide Capsules (for myeloma and lymphomas) and Dasatinib Tablets (for chronic myeloid leukemia and acute lymphoblastic leukemia). The approvals further establish Biocon's strength in vertically integrated, complex drug products for the US and international markets.
Market Impact and Strategic Importance
Tentative approval enables Biocon to bring Rivaroxaban into the US market after expiration of applicable patents or exclusivities. This places Biocon in a position to compete in the highly profitable US anticoagulant market, where Rivaroxaban (the generic for Xarelto®) is a high-value therapy for cardiovascular and thrombotic diseases.
Strengthening Global Portfolio:
These US FDA clearances demonstrate Biocon's continued focus on building its pipeline of complex generics, biosimilars, and specialty pharmaceuticals. The firm continues to invest in R&D and regulatory filings to boost its global presence and provide affordable, quality medicines.
Stock Market Reaction:
There was a modest rise in Biocon shares after the announcement, demonstrating investor faith in the company's regulatory advancements and growth opportunities.
Insight
The US FDA's conditional approval of Rivaroxaban Tablets is a strategic success for Biocon Pharma, paving the way for future entry in a significant therapeutic segment in the US. Coupled with recent final approvals for other oncology and hematology brands, Biocon is consolidating its position as a major supplier of complex and critical medicines to regulated markets.
Source: Biocon.com, Angel One ,Business Standard, Angel One
Advertisement
Advertisement
